title: Antacids reduce Campylobacter pylori colonization without healing the gastritis in patients with nonulcer dyspepsia and erosive prepyloric changes.
abstract: Antral biopsy specimens from 89 consecutive patients with nonulcer dyspepsia and erosive prepyloric changes included in a prospective, randomized, double-blind 4-wk study of the effect of an aluminum-magnesium antacid (120 mmol/day) or pirenzepine (50 mg b.i.d.) vs. placebo were examined histologically. Campylobacter pylori (CP) was found by light microscopy of silver-stained sections in 25 patients (28%). Campylobacter pylori-positive patients were on average older than CP-negative patients (p = 0.02). There was a strong association between CP colonization and acute inflammation (p less than 0.001), both being rare in the absence of chronic inflammation. During treatment with antacids, the density of CP decreased (p less than 0.001) without any improvement of the inflammatory reaction. On the contrary, the number of patients with gastritis tended to increase after antacids as compared with placebo (p less than 0.10). A separate analysis showed no symptomatic effect of the drugs. Thus, neither nonulcer dyspepsia nor erosive prepyloric changes are strongly associated with antral CP colonization or acute inflammation. Aluminum-magnesium antacids may suppress antral CP infection without healing the gastritis or relieving symptoms.
authors.affiliation: Division of Gastroenterology, University of Alabama at Birmingham.
authors.forename: A
authors.initials: A
authors.lastname: Berstad
authors.forename: B
authors.initials: B
authors.lastname: Alexander
authors.forename: R
authors.initials: R
authors.lastname: Weberg
authors.forename: A
authors.initials: A
authors.lastname: Serck-Hanssen
authors.forename: S
authors.initials: S
authors.lastname: Holland
authors.forename: B I
authors.initials: BI
authors.lastname: Hirschowitz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000863:Antacids / Q000627:therapeutic use*; D002167:Campylobacter / Q000187:drug effects* / Q000302:isolation & purification; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004415:Dyspepsia / Q000150:complications / Q000382:microbiology*; D005260:Female; D005753:Gastric Mucosa / Q000382:microbiology / Q000473:pathology*; D005756:Gastritis / Q000150:complications / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010890:Pirenzepine / Q000627:therapeutic use; D011446:Prospective Studies; D011706:Pyloric Antrum / Q000473:pathology; D011897:Random Allocation
chemical_list: D000863:Antacids; D010890:Pirenzepine